The Role of GLP-1 Medications in Fatty Liver Disease Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Wegovy) and tirzepatide (Mounjaro), were originally developed to manage type 2 diabetes
Ready in 20 minutes A delicious meal, cooked fresh for you
The relevance to humans is unknown, but semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Some compounded versions may offer alternative delivery methods
The product may be less suited for consumers who require transparent individual ingredient dosing for clinical comparison, those seeking a direct replacement for prescribed blood sugar medications, or individuals expecting rapid glucose changes from a single supplement without accompanying lifestyle modifications
Weekly injection regimens, such as those adopted by some GLP-1 receptor agonists, have already been met with patient preference due to the reduced frequency of administration compared to daily injections like basal insulin